WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H130172
CAS#: 2411771-95-2
Description: JS25 is a covalent inhibitor of Bruton’s tyrosine kinase (BTK) with the potential application as a treatment for hematological cancers. The sequestering of Tyr551 by JS25 was found to lead to the inactivation of BTK.
Hodoodo Cat#: H130172
Name: JS25
CAS#: 2411771-95-2
Chemical Formula: C23H20N4O4S
Exact Mass: 448.12
Molecular Weight: 448.500
Elemental Analysis: C, 61.60; H, 4.50; N, 12.49; O, 14.27; S, 7.15
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: JS25; JS 25; JS-25
IUPAC/Chemical Name: N-(3-methyl-5-(8-(methylsulfonamido)-2-oxobenzo[h][1,6]naphthyridin-1(2H)-yl)phenyl)acrylamide
InChi Key: IPECVULEINBBEW-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H20N4O4S/c1-4-21(28)25-17-9-14(2)10-18(11-17)27-22(29)8-5-15-13-24-20-12-16(26-32(3,30)31)6-7-19(20)23(15)27/h4-13,26H,1H2,2-3H3,(H,25,28)
SMILES Code: C=CC(NC1=CC(N2C(C=CC3=C2C4=CC=C(NS(=O)(C)=O)C=C4N=C3)=O)=CC(C)=C1)=O
Appearance: To be determined
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
Biological target: | |
In vitro activity: | |
In vivo activity: |
The following data is based on the product molecular weight 448.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
Formulation protocol: | |
In vitro protocol: | |
In vivo protocol: |
1. Sousa BB, de Almeida CR, Barahona AF, Lopes R, Martins-Logrado A, Cavaco M, Neves V, Carvalho LAR, Labão-Almeida C, Coelho AR, Leal Bento M, Lopes RMRM, Oliveira BL, Castanho MARB, Neumeister P, Deutsch A, Vladimer GI, Krall N, João C, Corzana F, Seixas JD, Fior R, Bernardes GJL. Selective Inhibition of Bruton's Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors. ACS Pharmacol Transl Sci. 2022 Nov 2;5(11):1156-1168. doi: 10.1021/acsptsci.2c00163. PMID: 36407952; PMCID: PMC9667546.